Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| MedPass International | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The study will evaluate the safety and performance of the ESTYME® MATRIX Round and Anatomical Silicone Gel-Filled Breast Implants in the breast augmentation and reconstruction.
The study will evaluate the safety and performance of the ESTYME® MATRIX Round and Anatomical Silicone Gel-Filled Breast Implants in the breast augmentation and reconstruction at 3 months, 1 year and 2 years post-procedure
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ESTYME MATRIX | Experimental | Participants who meet the requirements for breast augmentation or breast reconstruction surgeries and have been implanted with one or two ESTYME® MATRIX Breast Implant(s) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ESTYME® MATRIX Breast Implants | Device | Breast implant surgery in breast reconstruction or breast augmentation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Local complications | Evaluation of the safety 3 months post-implantation. Procedure-related adverse events/complications at 3 months post implant. Main foreseen complications: infection, haematoma, wound healing complication, fluid accumulation, early capsular contracture, rupture, extrusion. | 3 months |
| Satisfaction of the patient and the surgeon | Evaluation of the performance, 3 months post-implantation Performance endpoint will be assessed by implant procedure success at 3 months defined as follows:
| 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Local complications | Evaluation of the safety, 1 year and two years post-implantation. Safety endpoint: incidence of all Adverse Events (AE)/Serious Adverse Events (SAEs) @ 1 year and two years post procedure | 1 year and 2 years |
| Satisfaction of the patient and the surgeon |
Not provided
Inclusion Criteria:
Patient will be included if all of the following criteria are met:
Subject of between 18 and 65 years old
Candidate eligible for :
a. unilateral or bilateral breast augmentation i. general breast enlargement: cosmetic purposes, providing symmetry to opposite breast in case of unilateral surgery ii. surgical correction of various congenital or acquired anomalies such as amastia, aplasia, hypomastia, hypoplasia, asymmetries, Poland's syndrome, ptosis …
b. or immediate or delayed unilateral or bilateral breast reconstruction (for cancer, trauma, surgical loss of breast)
Patient signs PIC (Patient Informed Consent) & willing to comply with the protocol assessments and visits follow up
Exclusion Criteria:
Patient will not be included if any of the following conditions exists:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| EMMANUEL DELAY, MD | Clinique Charcot | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre F.X. Michelet Chu Bordeaux | Bordeaux | 33076 | France | |||
| Chu Pasteur |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Performance endpoints are as follows:
|
| 1 year and 2 years |
| Nice |
| 06000 |
| France |
| Clinique des Champs Elysées | Paris | 75008 | France |
| Clinique BIZET | Paris | 75016 | France |
| Institut du Sein | Paris | 75017 | France |
| Hopital Tenon | Paris | 75020 | France |
| Clinique Charcot | Sainte-Foy-lès-Lyon | 69500 | France |
| Institut Gustave Roussy | Villejuif | 94805 | France |